Previous 10 | Next 10 |
BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY PR Newswire MINNEAPOLIS , Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug...
LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS PR Newswire MINNEAPOLIS , Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, and SIB Sw...
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE PR Newswire MINNEAPOLIS , Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, and Kim...
2023-11-20 05:52:51 ET Summary Bio-Techne's shares have fallen by a quarter since May, but the long-term thesis remains intact. The company has experienced low single-digit sales growth due to macro issues, but long-term potential is still present. Valuations have become more ...
2023-11-17 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-08 13:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-05 09:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Growth Fund declined 3.66% during Q3 2023, outperforming the Russell 2000 Growth...
ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE PR Newswire Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 ...
Bio-Techne Corp (TECH) is expected to report $0.39 for Q1 2024
2023-10-31 16:08:09 ET Bio-Techne Corporation (TECH) Q1 2024 Earnings Conference Call October 31, 2023, 09:00 AM ET Company Participants David Clair - Vice President-Investor Relations Charles Kummeth - Chief Executive Officer James Hippel - Chief Financial Offic...
News, Short Squeeze, Breakout and More Instantly...
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES PR Newswire MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following invest...
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE PR Newswire MINNEAPOLIS , May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched Maurice...
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing PR Newswire ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio...